A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
Phase 1
- Conditions
- B-cell Malignancies
- Interventions
- Genetic: Therapeutic 4SCAR19 cells
- First Posted Date
- 2017-02-10
- Last Posted Date
- 2019-09-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 200
- Registration Number
- NCT03050190
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
🇨🇳The First People's Hospital of Yunnan, Kunming, Yunnan, China
Study on GD2 Positive Solid Tumors by 4SCAR-GD2
Phase 1
- Conditions
- Solid Tumor
- Interventions
- Genetic: 4SCAR-GD2
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2018-02-19
- Lead Sponsor
- Shenzhen Geno-Immune Medical Institute
- Target Recruit Count
- 100
- Registration Number
- NCT02992210
- Locations
- 🇨🇳
Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath